Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE)
| Autor: | Keisuke Hori, Hiroyuki Daiko, Takeshi Sakamoto, Junki Mizusawa, Ken Kato, Mitsumi Terada, Takashi Ogata, Tomohiro Kadota, Yuko Kitagawa, Katsuyuki Sakanaka, Hiroki Hara, Hirofumi Ogawa |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Esophageal Neoplasms Salvage therapy Docetaxel Japan Antineoplastic Combined Chemotherapy Protocols Carcinoma medicine Humans Combined Modality Therapy Radiology Nuclear Medicine and imaging Progression-free survival Aged Squamous Cell Carcinoma of Head and Neck business.industry Standard treatment Induction chemotherapy Chemoradiotherapy Induction Chemotherapy General Medicine Middle Aged medicine.disease Progression-Free Survival Oncology Female Fluorouracil Radiology Cisplatin Unresectable Esophageal Carcinoma business medicine.drug |
| Zdroj: | Japanese Journal of Clinical Oncology. 49:1055-1060 |
| ISSN: | 1465-3621 |
| DOI: | 10.1093/jjco/hyz112 |
| Popis: | A randomized phase III trial commenced in Japan in February 2018. Definitive chemoradiotherapy (CRT) with cisplatin plus 5-fluorouracil is the current standard treatment for locally advanced unresectable esophageal carcinoma. The purpose of this study is to confirm the superiority of induction chemotherapy with docetaxel plus cisplatin and 5-fluorouracil (DCF) followed by conversion surgery or definitive CRT over definitive CRT alone for overall survival (OS) in patients with locally advanced unresectable squamous-cell carcinoma of thoracic esophagus. A total of 230 patients will be accrued from 47 Japanese institutions over 4.5 years. The primary endpoint is OS, and the secondary endpoints are progression-free survival, complete response rate of CRT, response rate of DCF, adverse events of DCF and CRT, late adverse events and surgical complications. This trial has been registered at the Japan Registry of Clinical Trials as jRCTs031180181. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|